AV-GBM-1の新興薬剤に関する洞察と市場予測：2032年

AV-GBM-1は、培養した自己多形性膠芽腫（GBM）腫瘍細胞由来の自己複製腫瘍開始細胞に由来する自己腫瘍抗原を担持した自己樹状細胞からなる新規免疫療法であり、免疫賦活作用および抗腫瘍作用が期待されます。本治療法は、補助療法として一連のSC注射で投与されます。この治療薬はユニークな汎抗原性で、疾患の急速な増殖と標準治療に対する抵抗性の原因である自己腫瘍開始細胞上の複数の抗原を標的とします。AV-GBM-1を投与すると、自己のTAA担持DCが免疫系をGBM新抗原に暴露し、その結果、自己のGBM細胞に対する細胞傷害性Tリンパ球（CTL）媒介免疫応答が起こり、GBM細胞が溶解します。

Aivita Biomedicalは、AV-GBM-1を新たに診断されたGBMに対する潜在的治療薬として、第III相臨床試験で検討しています。

今後数年間で、多形性膠芽腫（GBM）の市場シナリオは、世界中の広範な研究と医療支出の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、AV-GBM-1の優位性に影響を与える可能性のある機会を模索しています。GBM-1を対象とする他の新興製品はAV-GBM-1と厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるAV-GBM-1市場について調査し、市場の概要とともに、2027年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 多形性膠芽腫（GBM）に対するAV-GBM-1の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 AV-GBM-1市場評価

• GBMに対するAV-GBM-1の市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるGBMに対するAV-GBM-1の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: AV-GBM-1, Clinical Trial Description, 2023
• Table 2: AV-GBM-1, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: AV-GBM-1 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: AV-GBM-1 Market Size in the US, in USD million (2019-2032)
• Table 7: AV-GBM-1 Market Size in Germany, in USD million (2019-2032)
• Table 8: AV-GBM-1 Market Size in France, in USD million (2019-2032)
• Table 9: AV-GBM-1 Market Size in Italy, in USD million (2019-2032)
• Table 10: AV-GBM-1 Market Size in Spain, in USD million (2019-2032)
• Table 11: AV-GBM-1 Market Size in the UK, in USD million (2019-2032)
• Table 12: AV-GBM-1 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: AV-GBM-1 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: AV-GBM-1 Market Size in the United States, USD million (2019-2032)
• Figure 3: AV-GBM-1 Market Size in Germany, USD million (2019-2032)
• Figure 4: AV-GBM-1 Market Size in France, USD million (2019-2032)
• Figure 5: AV-GBM-1 Market Size in Italy, USD million (2019-2032)
• Figure 6: AV-GBM-1 Market Size in Spain, USD million (2019-2032)
• Figure 7: AV-GBM-1 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: AV-GBM-1 Market Size in Japan, USD million (2019-2032)

“"AV-GBM-1 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about AV-GBM-1 for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the AV-GBM-1 for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the AV-GBM-1 for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AV-GBM-1 market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary:

AV-GBM-1 is novel immunotherapy consisting of autologous dendritic cells loaded with autologous tumor antigens derived from self-renewing tumor-initiating cells derived from cultured autologous glioblastoma multiforme (GBM) tumor cells, with potential immunostimulatory and antineoplastic activities. The treatment is administered in a series of SC injections as adjunctive therapy. It is uniquely pan-antigenic, targeting multiple antigens on autologous tumor-initiating cells responsible for the rapid growth of the disease and resistance to standard therapy. Upon administration, the autologous TAA-loaded DCs AV-GBM-1 expose the immune system to the GBM neoantigens, which results in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the autologous GBM cells leading to GBM cell lysis.

Aivita Biomedical investigates AV-GBM-1 as a potential treatment for newly diagnosed GBM in Phase III clinical trial.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the AV-GBM-1 description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on AV-GBM-1 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the AV-GBM-1 research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around AV-GBM-1.
• The report contains forecasted sales of AV-GBM-1 for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for AV-GBM-1 in GBM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AV-GBM-1 Analytical Perspective by DelveInsight

In-depth AV-GBM-1 Market Assessment

This report provides a detailed market assessment of AV-GBM-1 for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

AV-GBM-1 Clinical Assessment

The report provides the clinical trials information of AV-GBM-1 for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AV-GBM-1 dominance.
• Other emerging products for GBM are expected to give tough market competition to AV-GBM-1 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AV-GBM-1 in GBM.
• Our in-depth analysis of the forecasted sales data of AV-GBM-1 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AV-GBM-1 in GBM.

Key Questions:

• What is the product type, route of administration and mechanism of action of AV-GBM-1?
• What is the clinical trial status of the study related to AV-GBM-1 in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AV-GBM-1 development?
• What are the key designations that have been granted to AV-GBM-1 for GBM?
• What is the forecasted market scenario of AV-GBM-1 for GBM?
• What are the forecasted sales of AV-GBM-1 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to AV-GBM-1 for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?

Table of Contents

1. Report Introduction

2. AV-GBM-1 Overview in GBM

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. AV-GBM-1 Market Assessment

• 5.1. Market Outlook of AV-GBM-1 in GBM
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of AV-GBM-1 in the 7MM for GBM
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of AV-GBM-1 in the United States for GBM
  • 5.3.2. Market Size of AV-GBM-1 in Germany for GBM
  • 5.3.3. Market Size of AV-GBM-1 in France for GBM
  • 5.3.4. Market Size of AV-GBM-1 in Italy for GBM
  • 5.3.5. Market Size of AV-GBM-1 in Spain for GBM
  • 5.3.6. Market Size of AV-GBM-1 in the United Kingdom for GBM
  • 5.3.7. Market Size of AV-GBM-1 in Japan for GBM

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options